UNIT 5.47 Streptozotocin-Induced Diabetic Models in Mice and Rats

  1. Kenneth K. Wu1,
  2. Youming Huan2

Published Online: 1 MAR 2008

DOI: 10.1002/0471141755.ph0547s40

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Wu, K. K. and Huan, Y. 2008. Streptozotocin-Induced Diabetic Models in Mice and Rats. Current Protocols in Pharmacology. 40:5.47:5.47.1–5.47.14.

Author Information

  1. 1

    Merck Research Laboratories, Rahway, New Jersey

  2. 2

    Mount Sinai School of Medicine, New York, New York

Publication History

  1. Published Online: 1 MAR 2008
  2. Published Print: MAR 2008

This is not the most recent version of the article. View current version (1 SEP 2015)


Streptozotocin (STZ) is an antibiotic that can cause pancreatic β-cell destruction, so it is widely used experimentally as an agent capable of inducing insulin-dependent diabetes mellitus (IDDM), also known as type 1 diabetes mellitus (T1DM). This unit describes protocols for the production of insulin deficiency and hyperglycemia in mice and rats, using STZ. These models for diabetes can be employed for assessing the mechanisms of T1DM, screening potential therapies for the treatment of this condition, and evaluation of therapeutic options. Curr. Protoc. Pharmacol. 40:5.47.1-5.47.14. © 2008 by John Wiley & Sons, Inc.


  • streptozotocin;
  • type 1 diabetes mellitus;
  • hyperglycemia;
  • insulin deficiency;
  • insulitis;
  • mouse;
  • rat